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economic evaluations based on models, published in 2006 were
obtained from a PubMed search using terms “probabilistic sen-
sitivity” or “probabilistic uncertainty”. Methodological items
were extracted from each article and independently evaluated
against the criteria by each researcher. Disagreements between
evaluations were resolved through voting by the entire research
team. RESULTS: All 43 economic evaluations identiﬁed by the
search criteria were reviewed. 86% varied probability and
utility inputs but only a minority (25%) did so for cost and
resource use inputs. 79% of the studies reported parameter
ranges used in the PSA but only half provided rationale for the
ranges selected. The majority of analyses (65%) used a single
data source to inform distributions, rather than attempt to inte-
grate ﬁndings from multiple studies. Parameter correlation was
only addressed in one instance and only two studies incorpo-
rated structural uncertainty in their analyses. In half of the
studies, PSA was the only type of sensitivity analysis con-
ducted, with no one- or multi-way sensitivity analyses. Cost-
effectiveness acceptability curves derived from the PSAs were
presented in all cases. Less than 10% of studies discussed limi-
tations of their PSA. CONCLUSION: Although PSA has been
pushed as standard practice for economic evaluations, the
quality of these analyses was mixed. Greater consistency in
terms of inclusion of inputs varied and more transparency in
describing development of input probability distributions in the
conduct of PSAs should improve quality and cross-study com-
parability of results.
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OBJECTIVES: The Indigent Care Collaboration (ICC) gathers
data on hospital and clinic visits for medically indigent patients
in the Austin, Texas, area. However, obtaining cost data is
challenging within, and especially across, partner providers. A
validated cost model would be instrumental in developing pro-
grams and initiatives to improve care. The objectives of this
study were to estimate the annual costs of Austin, Texas, area
medically indigent patients and to describe the prevalence and
costs of chronic diseases and conditions using a diagnosis-based
risk adjustment model. METHODS: This study used the Diag-
nostic Cost Groups (DCG) prospective Medicaid All-
Encounters model, which uses diagnoses, age, and gender to
assign relative risk (RR) scores to patients. The RR scores were
multiplied by the per capita Texas Medicaid expenditure to
obtain estimated annual costs. Chronic diseases were described
in terms of prevalence and total estimated annual cost.
RESULTS: A total of 471,194 encounters were recorded for
163,729 patients meeting the study inclusion criteria between
March 1, 2004, and February 28, 2005. The mean estimated
patient yearly cost was $1,306.81, and the total estimated
yearly population cost was $228,909,529. The most common
chronic diseases and conditions included hypertension, diabe-
tes, depression, substance abuse, pregnancy, asthma, chronic
obstructive pulmonary disease (COPD), and congestive heart
failure (CHF). CONCLUSION: This study demonstrates how
the unknown costs associated with caring for medically indi-
gent patients in a community can be estimated at Medicaid
reimbursement rates using the DCG model on aggregated
patient encounter data.
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OBJECTIVES: The concept of efﬁcient frontier, given a series of
cost-effectiveness estimates for different levels of programs, plays
an important role in the incremental analysis. The purpose of the
study is to exploit a theoretical aspect of the incremental cost-
effectiveness ratios (ICERs) in the context of the efﬁcient frontier
curve, and then to identify the upper and lower limits that bound
the ICER, considering a potential application of the limits for the
pricing rule based on the ICER. METHODS: Let two points be
PA(Ea, Ca) and PB(Eb, Cb) for programs A and B, respectively,
on the E-C plane representing a set of effectiveness and cost.
Theoretical developments were undertaken to ﬁnd a solution for
the question on the boundaries, supposed there exists a concave
graph of the efﬁcient frontier curve, C = f(E), directing upward
from zero on the E-C plane. Model calculation was performed,
for an example, when the curve is a quadratic function estimated
as C = pE2 + qE + r (p, q, and r: constants). RESULTS: The inter-
val with the derivatives:(f ’(Ea), f ’(Eb)) on C = f(E), respectively,
at the points PA and PB was identiﬁed as a solution, called
‘operative interval,’ which describes reasonable lower/upper
boundaries of the ICER, considering the conﬁguration of the
graph. When the efﬁcient frontier curve is quadratic, the width of
the interval was estimated as 2p(DE). Namely, the width is vari-
able, not constant, depending on both p and DE. Furthermore,
the new benchmark identiﬁed four possible scenarios for making
a decision to accept the ICER compared with a threshold of
willingness-to-pay. CONCLUSION: The concept of the opera-
tive interval of an ICER has been introduced, and it suggested
potential usefulness for assessing the acceptability.
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OBJECTIVES: To explore the contribution made by disease
transmission modelling to cost effectiveness analyses.
METHODS: Traditional cost-effectiveness analysis quantiﬁes the
costs and effects accumulated by an average individual exposed
to a particular intervention, relative to one or more suitable
comparators. When reacting to an infectious disease, however,
many interventions alter the natural history of an infection or
individuals’ behaviour in ways that affect the onward transmis-
sion of the pathogen. This, in turn, may inﬂuence the number of
secondary infections generated by each infectious case. For a
cost-effectiveness analysis to account for the averted/additional
cases, a population level perspective including disease transmis-
sion modelling is required, but this comes at a cost. Transmission
models take time to construct and parameterise and are often
data hungry. Do the insights these models provide justify the
investment in time and expertise they require? RESULTS:
This exposition outlines the basic concepts underlying disease
transmission modelling, presents a simple model for a directly
transmitted disease (such as inﬂuenza) and demonstrates the
enormous impact population level effects can have on the
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outcome of a cost-effectiveness analysis. This impact is most
acute when the members of a large population can mix freely
(there is little compartmentalisation), for example across
different age groups, there is signiﬁcant transmission (the mean
number of secondary infections generated by each primary infec-
tion is greater than one) and where transmission is rapid (short
incubation period). This ﬁnal condition is important if the cost-
effectiveness analysis has a short time horizon, particularly where
costs are accumulated sooner than beneﬁts (as in a vaccination
program). This has been demonstrated in the analysis of both
varicella zoster and hepatitis B virus vaccination programs. The
circumstances in which transmission modelling is of greatest
value will be further discussed, as too will those in which an
individual based analysis sufﬁces.
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OBJECTIVES: The project AIDA (Atlas of Italian Administra-
tive Database) recently shown that collection of administrative
data in Italy is widespread both at national and local level; Aim
of this study is to evaluate the use of these databases in health
economics ﬁeld in Italy focusing on Friuli Venezia Giulia (FVG)
Region as pilot. METHODS: A Pubmed search was carried out
using 11 different key words to match studies based on admin-
istrative data collected on FVG population published till
December 2006. The articles included in the analysis were then
classiﬁed according to therapeutic area, period, data source,
population, other data. RESULTS: Initially our search identiﬁed
123 articles, but only 24 were eligible for inclusion in our
project. 7 studies were focused on drugs efﬁcacy and related
AEs, 8 studies estimated prevalence, incidence or risk factor of
some major diseases such as cancer, coronary or ischemic
disease; 6 studies evaluated the effectiveness of surveillance
campaigns and 2 studies were focused on quality of care pro-
vided by Regional Healthcare System. The articles were all pub-
lished in the period between 1990 and 2006, and 58% were
published in the last 7 year. All the studies included in the
analysis gave information about resources use and consumption
but only one study appraised the direct cost. Hospital discharge
records, prescriptions registries and disease registries were most
commonly used database in the eligible studies. CONCLU-
SION: FVG Healthcare Informative System is one of the best
developed and with the highest quality of data collection at a
local level in Italy, for this reason we have chosen it as pilot;
our search showed that in recent years use of administrative
data as proxy outcome and cost estimation was implemented
compared to years ’90 but they remain still underused in
Health Technology Assessment.
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OBJECTIVES: This study presents a methodology to estimate
prevalence rates for speciﬁc diagnosed conditions among
the ~170 million Americans covered by employer-sponsored
insurance (ESI). Individuals with ESI represent over 58% of the
U.S. population, a large group with fewer cost barriers to care.
METHODS: Estimates were made from the 2005 MarketScan®
databases, which include all health care claims for approximately
20 million employees, dependents, and retirees with ESI. The
Sample Select Prevalence tool identiﬁed patients diagnosed with
asthma, osteoporosis, allergic rhinitis (AR), essential hyperten-
sion, rheumatoid arthritis (RA), type II diabetes, congestive
heart failure (CHF), or hypercholesterolemia (using relevant
ICD-9-CM diagnosis codes), and calculated prevalence rates.
Weights were developed based on the Medical Expenditure
Panel Survey (MEPS), a probability sample that estimates the
number of Americans by health insurance type. The ratio of
MEPS population estimate to MarketScan population within
certain strata of demographic characteristics provided the pro-
jection weights. Prevalence rates were calculated for the total
population and by age, gender, geographic region, and health
plan type. RESULTS: Based on the 2005 MarketScan data-
bases, annual rates per 100,000 were as follows: 11,175.69
(hypertension), 4,813.54 (type II diabetes), 4,739.46 (AR),
4,275.79 (hypercholesterolemia), 3,164.33 (asthma), 962.80
(osteoporosis), 736.29 (CHF), 521.59 (RA). These rates varied
by age, gender, and geography. Annual expenditures per patient
ranged from $5,788 (AR) to $37,105 (CHF). CONCLUSION:
Reliable estimates of prevalence and costs for diagnosed health
conditions are valuable to policy makers, providers, and payers.
This study demonstrates a reliable projection methodology for
estimating annual prevalence, treatment events, and costs asso-
ciated with a diagnosed disease or condition based on a large
convenience sample of health care claims data.
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OBJECTIVES: The Expected Value of Perfect Parameter Infor-
mation (EVPPI) requires three level simulation in non-linear
micro-simulation models, which is time consuming. Meta-
modelling approaches reduce the time needed to evaluate the
inﬂuence of uncertainty in complex health economic models.
Here, two meta-modelling approaches are compared: spatial
interpolation (SI) and ordinary least squares (OLS).
METHODS: Both methods are applied to a drug-drug com-
parison in a micro-simulation schizophrenia model. The Net
Beneﬁts appear to depend rather non linearly on the underlying
variables as assessed using the R2 and the RESET-test. Ordi-
nary least squares is applied using 950 model runs. SI is applied
using 100 and 950 model runs. Subsequently both meta-
modelling methods are used to predict 50 out-of-sample runs
and evaluated with the Root Mean Squared Prediction Error
(RMSPE) and the time needed to estimate the EVPPI.
RESULTS: One run of the micro-simulation model takes 11
minutes. The SI 950 is more accurate than the OLS and SI 100,
which are comparable (average RMSPE for net beneﬁts for two
treatments 3006, 4842, and 4823 respectively). The SI 950
EVPPI calculation takes much longer time to complete the cal-
culations; the SI 100 on the other hand is much quicker than
the OLS (11005 minutes for the OLS and 2672 minutes for the
SI 100). CONCLUSION: The SI is a frequentistic approach
with great resemblance with the Bayesian Gaussian Process
meta-modeling method. If a simulation model takes very long
to come up with results or the model is non-linear, SI is the
superior meta-modelling technique. If the model is linear, SI is
fancy but not ideal.
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